Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company’s next-generation CGM+ biosensor platformDUBLIN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling positive clinical trial results demonstrating a major technical breakthrough and de-risking th ...